Atlas Trials

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Clinical trial NCT01434472 · TERMINATED

Trial details

NCT number
NCT01434472
Sponsor
Fred Hutchinson Cancer Center
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2011-11-16
Primary completion
2020-05-06
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.